[A19-84] Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
|2020-04-02||Extract of dossier assessment (German version)||104 kB|
|2020-04-02||Dossier assessment (German version)||2 MB|
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-01-02.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.